Posts
BrightSpring’s IPO Comeback?
After filing an S-1 in October 2021, then pulling the plug on those IPO plans in late 2022, BrightSpring IPO rumors have re-emerged. The home health and hospice player generated $5.6B in revenue in 2020, and more details to come as it files an updated S-1 assuming IPO plans go through and the healthcare public markets thaw out. BrightSpring’s footprint is impressive with 900+ locations across the U.S. and provision of care for complex patient populations (IDD, polypharma) (Link)
Read More3 key metrics for culture:
This quarter I’ve been focused on different aspects of culture from what it is to what can impact your company culture. I wanted to wrap up with how to measure your culture. Is it even possible to measure culture? Yes and no. Measuring culture can be complicated because: But that doesn’t mean you shouldn’t try…
Read MoreA Healthier Gambling App
3 FINTECH NEWS STORIES #1: A Healthier Gambling App What happened? A new neobank offering prize-linked savings accounts (PLSAs) raised a seed round: Layup, a challenger bank offering prize-linked savings accounts for sports fans, today announced a seed fundraising round of $2.3 million. The company will use the funds to expand product capabilities, recruit top…
Read MoreNot a death sentence
What it means to see venture-backed climate tech companies grappling with down rounds and what that portends for the sector as a whole.
Read MoreSwipe File – Ad Creatives
^ I made this for us. The best brands copy each other. Why be original when you can take the original and make it better! And, extra credit for taking ad creatives inspiration from outside of your specific niche. If you’re a skincare brand, copy skincare but also haircare but also your favorite fashion brand…
Read MoreSemaglutide: A Medical Marvel or an Economic Enigma?
Novo Nordisk’s semaglutide added another win to its books, this time showing significant reductions in symptoms in patients with heart failure with preserved ejection fraction (HFpEF). Are you asking yourself, “Geez, what can’t this drug do?” You’re not alone. In this article, I’ll summarize the latest STEP-HFpEF clinical trial, highlight semaglutide’s history thus far, and tie it…
Read More